Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03225963

Enrollment

Registered

2017-07-21

Start date

2015-08-01

Completion date

2018-07-31

Last updated

2017-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angiogenesis, Glioblastoma Multiforme

Keywords

Glioblastoma, Bevacizumab

Brief summary

Bevacizumab has become the standard of care of recurrent glioblastoma based on promising clinical trial results with with response rates up to 50% and progression-free survival up to 9 months. In our study, we set to find the serum angiogenesis biomarkers of bevacizumab response.

Detailed description

Pre-chemoradiation and post-chemoradiation peripheral blood will be obtained to see if there are some angiogenesis biomarker available for prediction of bevacizumab response later.

Interventions

RADIATIONChemoradiation with temozolomide

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Age older than 20 year old. * Glioblastoma patients who will receive chemoradiation treatment.

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
Response of bevacizumab therapy.	3 months after bevacizumab therapy	Base on the image after bevacizumab therapy (after recurrence)

Countries

Taiwan

Contacts

Primary ContactWeir Chiang You, M.D. Ph.D.

bigjohnyou@vghtc.gov.tw886-4-23592525

Backup ContactHui Lin Yeh, M.D.

yehl@vghtc.gov.tw886-4-23592525

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026